SCHEMBL693112

SCHEMBL693112

O=C(NS(=O)(=O)Cc1ccccc1)c1cccc(-c2ccc(OCCc3ccc(Cl)cc3)nn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 8/20 0.44
MCL1 Q07820 8/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
P4HTM Q9NXG6 1/20 0.41
GPR52 Q9Y2T5 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
KAT6A Q92794 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692973 0.90 MEN1 (0.47) BCL2L1MCL1MEN1KMT2AGPR52
SCHEMBL692997 0.83 BCL2L1 (0.53) BCL2L1MCL1GPR52TP53MAPT
SCHEMBL692593 0.83 NR4A2 (0.48) MEN1KMT2AGPR52NR1H4
SCHEMBL693063 0.82 BCL2L1 (0.46) BCL2L1MCL1GPR52TP53MAPT
SCHEMBL692561 0.81 BCL2L1 (0.51) BCL2L1MCL1MEN1KMT2ATP53
SCHEMBL692474 0.80 BCL2L1 (0.47) BCL2L1MCL1TP53MAPT
SCHEMBL692183 0.80 TP53 (0.52) BCL2L1MCL1MEN1KMT2AGPR52
Fluorobenzene SCHEMBL6114807 0.76 GPR52 (0.43) MEN1KMT2AGPR52NR1H4TP53
SCHEMBL692523 0.74 MAPT (0.58) MEN1KMT2ATP53MAPTNPC1
SCHEMBL6114840 0.74 GPR52 (0.41) MEN1KMT2AGPR52TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP claimed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US claimed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP claimed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US claimed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO claimed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO claimed
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 BCL2L1 2378/4885MCL1 3410/4885MEN1 2920/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 BCL2L1 2945/4885MCL1 1854/4885MEN1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.